Global Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor Pipeline Report 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 20, 2018--The “Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor - Pipeline Insight, 2018 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Descriptive coverage of pipeline development activities for Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Overview
3. Pipeline Therapeutics
An Overview of Pipeline Products4. Comparative Analysis
5. Pipeline Products in Clinical Stages
Product Description Research and Development Product Development Activities6. Pipeline Products in Non-clinical Stages
Product Description Research and Development Product Development Activities7. Therapeutic Assessment: Active Products
Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type8. Inactive Pipeline Products
Product Description Research and Development Product Development Activities Reason for dormancy/discontinuationCompanies Mentioned
Tiziana Life Sciences plc MetaMax Tragara Pharmaceuticals Merck Sharp & Dohme Corp. Bayer HealthCare Pharmaceuticals Piramal Enterprises Merck Onconova Therapeutics Presage Biosciences Jiangsu HengRui Medicine Roche PharmFor more information about this drug pipelines report visit https://www.researchandmarkets.com/research/l5rq4t/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181220005819/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs, Enzymes
KEYWORD:
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/20/2018 02:54 PM/DISC: 12/20/2018 02:54 PM
http://www.businesswire.com/news/home/20181220005819/en